Iurchenkov, A.; Danilova, A.; Shilo, P.; Stoliarov, V.; Rakhmanova, P.; Kanner, I.; Basharina, A.; Stroyakovskiy, D.
Real-World Outcomes of Nivolumab Plus Ipilimumab in Metastatic Melanoma: A Stratified Analysis of First- and Second-Line Treatment. Cancers 2026, 18, 1994.
https://doi.org/10.3390/cancers18121994
AMA Style
Iurchenkov A, Danilova A, Shilo P, Stoliarov V, Rakhmanova P, Kanner I, Basharina A, Stroyakovskiy D.
Real-World Outcomes of Nivolumab Plus Ipilimumab in Metastatic Melanoma: A Stratified Analysis of First- and Second-Line Treatment. Cancers. 2026; 18(12):1994.
https://doi.org/10.3390/cancers18121994
Chicago/Turabian Style
Iurchenkov, Alexandr, Anastasia Danilova, Polina Shilo, Vladimir Stoliarov, Polina Rakhmanova, Ilia Kanner, Anna Basharina, and Daniil Stroyakovskiy.
2026. "Real-World Outcomes of Nivolumab Plus Ipilimumab in Metastatic Melanoma: A Stratified Analysis of First- and Second-Line Treatment" Cancers 18, no. 12: 1994.
https://doi.org/10.3390/cancers18121994
APA Style
Iurchenkov, A., Danilova, A., Shilo, P., Stoliarov, V., Rakhmanova, P., Kanner, I., Basharina, A., & Stroyakovskiy, D.
(2026). Real-World Outcomes of Nivolumab Plus Ipilimumab in Metastatic Melanoma: A Stratified Analysis of First- and Second-Line Treatment. Cancers, 18(12), 1994.
https://doi.org/10.3390/cancers18121994
